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Abstract
Background: Plasma cell dyscrasias (PCD) are a spectrum of disorders resulting from the clonal expansion of plasma
cells, ranging from the pre-malignant condition monoclonal gammopathy of undetermined significance (MGUS) to
multiple myeloma (MM). MM generates a significant burden of disease on the community and it is predicted that it
will increase in both incidence and prevalence owing to an ageing population and longer survival secondary to new
therapeutic options. Robust and comprehensive clinical data are currently lacking but are required to define current
diagnostic, investigational and management patterns in Australia and New Zealand (ANZ) for comparison to both local
and international guidelines for standards of care. A clinical registry can provide this information and subsequently
support development of strategies to address any differences, including providing a platform for clinical trials. The
Myeloma and Related Diseases Registry (MRDR) was developed to monitor and explore variations in practices,
processes and outcomes in ANZ and provide benchmark outcomes nationally and internationally for PCD. This paper
describes the MRDR aims, development and implementation and discusses challenges encountered in the process.
Methods: The MRDR was established in 2012 as an online database for a multi-centre collaboration across ANZ,
collecting prospective data on patients with a diagnosis of MGUS, MM, solitary plasmacytoma or plasma cell leukaemia.
Development of the MRDR required multi-disciplinary team participation, IT and biostatistical support as well as
financial resources.
Results: More than 1250 patients have been enrolled at 23 sites to date. Here we describe how database
development, data entry and securing ethics approval have been major challenges for participating sites and the
coordinating centre, and our approaches to resolving them. Now established, the MRDR will provide clinically relevant
and credible monitoring, therapy and ‘real world’ outcome data, to support the conduction of high quality studies. In
addition, the Myeloma 1000 sub-study is establishing a repository of paired peripheral blood specimens from registry
patients to study mechanisms underlying disease progression.
Conclusion: Establishment of the MRDR has been challenging, but it is a valuable investment that will provide a
platform for coordinated national and international collaboration for clinical research in PCD in ANZ.
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Background
Plasma cell dyscrasias (PCD) are a spectrum of disorders
resulting from the clonal expansion of terminally differ-
entiated B-cells known as plasma cells. PCD range from
the pre-malignant monoclonal gammopathy of undeter-
mined significance (MGUS) to multiple myeloma (MM).
Patients with MGUS have a risk of progression to MM
of 1 % per year [1]. MM is the second most common
haematological malignancy, has a significant community
disease burden [2, 3] and is predominantly a disease of
the elderly with a median age at diagnosis of approxi-
mately 70 years [4]. While the overall prognosis for MM
remains poor and the disease is considered incurable
with pharmacotherapy, the introduction of new therap-
ies including proteasome inhibitors (PI) and immuno-
modulatory drugs (IMID) has resulted in a significant
improvement in MM outcomes, including the duration
of survival [5–8]. Improved survival combined with an
ageing population is predicted to result in an increase in
both the incidence and prevalence of MM in the next
few decades.
Currently, limited robust and comprehensive clinical
data exist, including demographics, current management
and outcomes for patients with MM and related diseases
in Australia and New Zealand (ANZ). These data are re-
quired to define the current diagnostic, investigational
and treatment patterns in ANZ for comparison to both
local and international guidelines for standards of care.
A clinical registry can provide this information and sub-
sequently support development of research and strat-
egies to address any differences and assess their impact
on clinical outcomes.
Clinical registries
Population-based cancer registries are well established in
Australia [9, 10]. These registries provide broad popula-
tion health surveillance and research support, however,
they typically do not provide sufficient detail for accurate
staging, treatment or outcome data with the exception
of survival. Cancer Australia has labelled these data ‘fun-
damental’[9] and in November 2010, in answer to this
unmet need, the Australian Health Ministers’ Confer-
ence (AHMC) endorsed the “Strategic and Operating
Principles for Australian Clinical Quality Registries”, for
a national approach to Australian clinical quality regis-
tries [11, 12]. A clinical-quality registry can be defined as a
dataset of pre-defined information from a group of patients
with a particular disease, using a particular health care re-
source or undergoing a particular procedure [13, 14]. Clin-
ical registries are able to provide high quality data allowing
monitoring of health care utilisation and therapy patterns
as well as detailed outcome data. These data are useful in
benchmarking clinical outcomes over large geographical
areas particularly in rare conditions where data from other
sources are often lacking.
All new histological diagnoses of cancer in ANZ are
required to be reported to state-based cancer registries
along with mortality data. These data, although valuable,
are inadequate for the analysis of treatment patterns or
therapy response. Currently there is no National Mini-
mum Data Set for cancer-related data; however, ‘The
Cancer (clinical) Data Set Specification’ is recommended
as best practice [15]. Linkage of these data to more ex-
tensive clinical and psychosocial data allows enhance-
ment of service provision, treatments and outcomes for
patients affected by these conditions [16]. This is par-
ticularly important in the case of PCD as the diagnosis
requires consideration of both clinical and pathological
features. As such, the differentiation between the various
PCD is not possible based on the data available to the
state-based cancer registries, limiting the validity of any
survival analyses and other assessments [17].
The Myeloma and Related Diseases Registry (MRDR)
was developed to monitor and explore variations in
practices, processes and outcomes in the ANZ setting
and provide benchmark outcomes nationally and inter-
nationally for PCD. The registry is also intended to act
as a resource for future clinical trials and projects such
as M1000, a MRDR sub-study which is establishing a re-
pository of paired peripheral blood specimens from
registry patients to study mechanisms underlying disease
progression. This article describes the aims, develop-
ment and implementation of the MRDR and discusses
some of the challenges experienced in the process.
Methods
Implementation
Clinical registries, although immensely useful, are diffi-
cult to initially develop and implement, requiring the in-
volvement of a multi-disciplinary team, including at a
minimum, patient groups, data collectors, clinicians, in-
formation technology (IT) and allied health staff. Biostat-
istical support is also mandatory to enable the robust
analysis of acquired data. Ideally a clinical registry would
collect all data for the population of interest at all time
points, however, the comprehensiveness of a database
needs to be weighed against the simplicity of use for the
overall best outcome. A suggested timeline for the devel-
opment of a clinical registry is shown in Table 1.
Resources
A team of researchers and collaborators with clinical, re-
search and epidemiological expertise was assembled to
develop the study concepts and to contribute to initial
project scoping, including data items to be collected,
pilot sites to be approached, and plans for analysis of
registry data. A partnership with Monash University was
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established through the Department of Epidemiology
and Preventive Medicine (DEPM), which has an inter-
nationally recognised academic epidemiology unit with
expertise in registry development, informatics and man-
agement of similar clinical registries in ANZ.
Not infrequently clinical registries are established prior
to the confirmation of the resources required, relying on
the good will of clinical and clerical staff for data entry,
in addition to their existing workload. Personnel time is
not an insignificant resource requirement for the MRDR
as data entry requires approximately 45–60 min for a
new patient and 15–30 min for each review thereafter.
Payment to hospital sites for complete data on registered
patients is ideal but may not be feasible.
At inception the major initial requirements for the
MRDR were administrative and financial. Procurement
of funding for clinical registries is difficult as they do not
fit into traditional research funding schemes designed
for clinical trials, therefore, investigators need to source
funding via new and innovative methods. Funding re-
quired for clinical registries is unique to the individual
needs of a particular registry. In general, costs to consider
when planning a registry budget include staff time for pro-
ject management, submissions for human research ethics
committee approvals, initial database development and
maintenance, data entry and management, case ascertain-
ment and data linkage costs, and preparation of reports to
participating sites. Seed funding for the MRDR was se-
cured via grants from both the pharmaceutical industry
and Myeloma Australia leveraging established links with
the clinical experts involved in the creation of the registry.
These funds were used to design and build an individua-
lised, web-based software platform with a user-friendly
interface and were sufficient for the initial set up and the
first 2–3 years of registry operations. It was recognised
that a commitment of ongoing financial support from
government agencies would be desirable and that this
would require the demonstration of quality improvement
in the diagnosis and management of PCD for patients and
the health care sector. This will be achieved through re-
ports and publications of registry data with the potential
to translate into both policy and practice change.
Database architecture and design
The MRDR is a web based application and the security
and robustness of the system is determined by its archi-
tecture, servicing and monitoring. Data is stored on a
separate secure server to the web application providing
additional data security should the web server be brea-
ched. There is restricted access with a unique access
port to the web server controlled by firewalls. An IP Sec
tunnel between servers ensures a secure conduit for all
data which are encrypted with strong secure sockets
layer (SSL) encryption. The system requires continual
servicing and monitoring with service patches to ensure
there are no vulnerabilities in the architecture. Periodic
penetration testing and regular updates of the authorised
user access list are undertaken with security logging of
attempts to access the system and audit logs of database
changes to help to identify suspicious activity.
Governance
A steering committee was established to define clear ob-
jectives and provide project and research guidance and
oversight. Members were selected to provide guidance
on all aspects integral to the development, implementa-
tion and management of the registry. Members include
haematologists with track records of leadership and ex-
pertise in the management of MM, from the different re-
gions likely to be involved in the registry, a specialist
MM nurse consultant, a MM consumer group represen-
tative and researchers and a database expert from the
DEPM. In conjunction with an operations committee,
the steering committee facilitated the design, content
and structure of the registry utilising the varied skill sets
of individual members. The steering committee meets
every 3–4 months via teleconference to discuss progress
and plans for continued registry development in addition
to any issues reported by the sites. The full terms of ref-
erence of the steering committee are shown in Table 2.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were selected by the
steering committee to be as inclusive of target MM and
related disease cases as possible while still specific
Table 1 Suggested timeline for development of a clinical
registry
Pre-development Phase (0–6 months)
• Secure funding
• Finalise project plan
• Establish Steering Committee
Development phase (6–12 months)
• Finalise data set and data dictionary
• Web-database construction
• Establish contacts at 4–6 pilot hospitals
• Ethics submission at selected academic unit or central site and pilot
sites
Implementation Phase (1 year onwards)
• Data collection commences at 4–6 pilot sites
• Identify additional sites for inclusion in the Registry
Expansion Phase (18 months onwards)
• Ethics submission at additional sites
• Data collection commences at additional sites
• Test and develop new or improved measures of outcome
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enough to produce usable and robust data. Cases were
initially defined as incident cases of “myeloma or a re-
lated disease” in accordance with the International Mye-
loma Working Group (IMWG) diagnostic criteria [17].
Minimal revisions of the definition of “myeloma or a re-
lated disease” by the steering committee members with
clinical expertise were required to improve ease of data
collection with the only major change being the removal
of systemic amyloidosis and specific inclusion of plasma
cell leukaemia (PCL). “Myeloma or a related disease”
was ultimately defined as one of MGUS, MM, solitary
plasmacytoma, or PCL. An incident case was defined as
a diagnosis of MM or a related disease or a death attrib-
utable to MM or a related disease with diagnosis no
more than 3 months prior to ethics approval at the re-
spective site to ensure the integrity of the registry as a
prospective database. While ensuring the capture of a
meaningful proportion of MGUS patients at any particu-
lar site is difficult, as data from this patient population
are limited through other avenues, it is of particular
interest, especially in relation to progression to symp-
tomatic MM. Other non-disease specific inclusion and
exclusion criteria were minimised to facilitate a cohort
that is as complete and representative of real life practice
as possible. These criteria only stipulated an adult popu-
lation (age ≥18 years) who had not chosen to ‘opt off ’
the registry (see “Ethics” below). Final acceptance of the
inclusion and exclusion criteria was approved by the
steering committee led by the principle investigator.
Data selection
Data item selection for inclusion on a clinical registry is
a critical component that defines the quality and clinical
usefulness of the eventual output. The clinical research
expertise of the steering committee with track records in
investigator-initiated clinical trials and database develop-
ment and use, informed the content of a proposed prac-
tical and useful dataset. Usefulness of the dataset was
primarily judged by predicted ability of outcome data ex-
traction by the clinicians on the steering committee in-
cluding demographic variables, treatment details and
clinical, radiological and laboratory variables required
for therapy response assignment. These variables were
then discussed with all members of the steering commit-
tee to ensure the final dataset would be both clinically
useful and practical for data collectors as well as suitable
for use with the IT software to produce useful data ex-
traction results. In addition, discussion with other re-
search groups involved in established clinical registries
provided insights into clinical data of importance for in-
clusion to avoid preventable future missing data. Great
care was taken in configuration of the interface of the
database to ensure user-friendliness with drop-down
boxes favoured for categorical data, and minimal areas
requiring free text. Decisions on the therapy data required
were guided by both clinical utility and availability for col-
lection by non-medically trained data-entry staff. Data se-
lected for inclusion included demographic data, diagnosis
data, therapy and supportive care administered, disease re-
sponses and survival (shown in Table 3).
MM and related diseases represent a complex niche area
of haematology that many data collectors may not be famil-
iar with, resulting in the possibility of inaccurate entry, par-
ticularly with respect to therapeutic responses. To counter
this, extra data points were collected to enable independent
assessment of response by MRDR MM experts. This infor-
mation was then converted into a functional online data-
base by a professional clinical informatics team that is
accessed directly by participating sites.
Clinical registries such as the MRDR are by nature
non-interventional and dynamic, describing the natural
history of the disorders and therapies used in their man-
agement over time. MM typically relapses following
treatment and remains incurable with current therapies.
Key time points based on a typical patient’s diagnostic
process, subsequent initiation of treatment and routine
Table 2 Terms of reference of the Steering Committee
Terms of reference of the Steering Committee include:
• Monitor the scientific progress of the project including the data quality
• Advise on the collection and interpretation of data
• Assess and advise regarding performance outliers
• Advise on scientific priorities to be addressed in data analysis and
publication strategy
• Review publications of the project and advise on their scientific quality
• Review all research and external data requests
Table 3 Key Data Entry Time Points and Data Items





• Health at diagnosis
• Demographic Details
• Laboratory and imaging results at diagnosis
Changes in treatment
regimen
• Therapy decisions including including pre
therapy benchmarking, chemotherapy,
autologous stem cell transplants, allogeneic








• Myeloma markers as per IMWG criteria
• Date of disease progression or relapse
Treatment response • Response as per IMWG criteria
• Outcomes (overall and progression free
survival, duration of response and time to next
treatment and quality of life measures – EQ-
5D-5L)
Date (and cause) of
death
• Long-term outcomes (through linkage with
Cancer and Death Registries).
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follow-up were agreed upon by a consensus of opinion
of the clinical members of the steering committee.
Registry outputs were to include detailed patient and
disease demographics, treatment selection and delivery,
and subsequent correlation with disease response (see
Table 3). Due to the clinically heterogeneous and relaps-
ing nature of MM these time points may be difficult to
predict implying that continual data collector review is
required. To overcome this, a review period of 4 months
for MM and PCL and annually for MGUS and solitary
plasmacytoma, reflecting the natural history of these dis-
orders, was agreed upon to balance the risk of missing
important information while ensuring a manageable
workload for hospital data collectors. The choice of
these review periods has ensured data collection is not
excessively onerous, necessitating data collectors on only
a part time basis for most sites. As the MRDR matures
with larger numbers of patients registered requiring on-
going review these personnel resource needs will in-
crease and review periods may need to be reassessed
and modified.
It is hoped that with time larger numbers of patients
will be registered on the MRDR with maturing data cre-
ating significant research output. These outputs will
ideally result in funding opportunities providing sites
with further financial support for ongoing data collec-




The Australia and New Zealand Myeloma and Related
Diseases Registry was established in 2012. Currently
there are 23 approved sites, including 20 Australian and
three New Zealand sites, with nine more sites in the
process of obtaining ethical approval to participate as of
September, 2016. Patient registrations reached 1000 in
March, 2016 with over 1250 patients enrolled as of Sep-
tember, 2016.
Research output and communication
The MRDR uses several forums to update stakeholders,
share information with supporters and collaborators,
and invite participation. Regular updates are included in
publications for myeloma patient and specialist clinician
groups and the registry circulates a periodic newsletter
for interested parties including clinicians, nursing staff,
patients, industry and community sponsors. An annual
MRDR interest group breakfast meeting is held at the
major ANZ haematology conference and MRDR data
has also been presented at national and international
medical conferences.
Analysis of registry data is undertaken by MRDR staff
working in the DEPM at Monash University. These data
are interpreted with the input of specialist clinicians on
the steering committee. A PhD student associated with
the MRDR contributes to clinical input, analysis and
publication. The first comprehensive evaluation of the
epidemiology and current treatment of MM in ANZ
using registry data is in preparation for publication.
Discussion
Case identification and registration
The aim of the MRDR is the creation of a population-
based registry to monitor and explore variation in prac-
tices, processes and outcomes for PCD in ANZ, and to
provide data for benchmarking nationally and inter-
nationally. Initial patient registration is completed by cli-
nicians after identifying appropriate patients in the
clinic. A truly population-based registry requires as close
as possible to 100 % coverage of all sites that manage
PCD in ANZ, both in the public and private sector. Sites
where members of the steering committee held clinical
appointments were the first sites to register patients,
then further sites suggested by steering committee mem-
bers were approached. Once the profile of the registry
grew clinicians began to actively seek involvement. How-
ever, to improve the inclusiveness and clinical usefulness
of data, under-represented areas including non-Victorian,
rural and private sector sites are now prioritised. Participa-
tion by these sites is being actively sought by direct email
contact and networking at local, national and international
meetings and conferences. Additional assistance for site
set-up is also provided by the MRDR team including a
mock online database for demonstration of the required
data input, and support with ethics submissions.
Quality control - case ascertainment and audits
Case ascertainment at participating sites will be moni-
tored through linkage with state and national cancer
registry data, with missing or discrepant cases followed
up with local sites to ensure that close to 100 % of cases
are registered. Comparison of patients registered on the
MRDR with patients registered on the Victorian Cancer
Registry from participating Victorian sites is underway.
As the number of interstate sites grows, arrangements
with other state based cancer registries are being pur-
sued. In addition, sites’ ability to access their own data
for review facilitates data completion and the opportun-
ity for local audits. Completeness of key data points is
assessed and fed back to sites in biannual reports, pro-
moting and enhancing data completeness and quality.
Audits of 5 % of registry cases against source data will
also assess accuracy and completeness of data collection.
Clinical feedback for participating sites
Benefits of involvement with the MRDR include clinical
feedback on data entered. Initially data was only
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provided to sites in aggregate form. Feedback from the
sites to the steering committee suggested that this did
not allow individual sites sufficient information to reflect
on their own management practice. This prompted a
change, with an online data extraction link provided to
all sites, which allows individual sites access to their own
data. This allows them to evaluate their practice and
provides an incentive for data completion and ongoing
registry participation.
Continuity of patient access
An advantage of patient registration on the MRDR lies
in its ability to provide comprehensive clinically useful
data on cohorts of patients. In real life clinical practice if
a patient is referred to another centre for ongoing care
the patient is often lost to follow up by the initial treat-
ing clinician. The recognition of this has enabled a re-
cent modification to the database that now permits
transfer (and return) of patient data from one centre to
another within the registry. This allows clinicians to as-
sess the treatment and outcome data of their patients
even after referral and ensures that the patient will be
included in the corresponding site’s biannual reports,
thus enabling each site to maintain an accurate and
complete picture of their patient cohort.
Ethical and privacy considerations
Involvement of multiple sites requires ethics approvals
from the Human Research Ethics Committee (or equiva-
lent) at each institution. Privacy legislation in Australia
allows ‘opt off ’ consent models for activities like regis-
tries where the minimal impingement on individual priv-
acy rights from participation is likely to be outweighed
by the public interest of having data available [18]. For
simplicity and maximum participation such an ‘opt off ’
consent model was adopted, with clinicians inviting pa-
tient participation in the registry and providing a written
brochure. The information brochure describes the na-
ture and purpose of the registry and requirements for in-
volvement. Contact details and information to ‘opt off ’
the registry are also provided. Only two patients have
chosen to ‘opt off ’ at the time of writing. This may re-
flect the fact that the data collected does not exceed that
routinely collected by clinicians for direct patient man-
agement, therefore participation is not perceived by pa-
tients as being onerous or intrusive.
Ethics submissions in ANZ can be lengthy and time-
consuming processes, creating further strain on the
already stretched financial and personnel resources of
individual sites. Some hospital ethics committees are un-
familiar with the ‘opt off ’ model, as it is very different
from the framework used for clinical trials, and some
have been hesitant to approve such submissions. How-
ever, the MRDR steering committee and Project
Manager provide practical, hands-on support to sites in
the preparation of materials for, and management of eth-
ics submissions. Streamlined ethics processes already in
place for clinical trials in ANZ have recently been ex-
tended to registries, which will help future site recruit-
ment and initiation.
Requirements for stakeholders wishing to store identi-
fied data on New Zealanders in overseas hosted services
have changed recently. An accepted overseas-based
cloud or hosting service must be used, or alternatively
an exemption must be obtained.
Further research
Sites have received their first reports providing a sum-
mary of key clinical performance and quality indicators
for their sites in comparison with overall results for all
patients on the MRDR. This information will facilitate
local comparative evaluation to support practice im-
provement and over time, change in practice at sites will
be monitored and evaluated to assess the impact of site
reports. In addition, sites can analyse, present and pub-
lish their own data from the MRDR. Other parties may
apply for data for research purposes, in accordance with
MRDR Data Access Policy guidelines.
One of the key aims of the registry is to act as a re-
source for further research. Proposals for MRDR-related
studies are invited regularly by email and inclusion in
the regular newsletter from all parties involved with or
with an interest in the MRDR. Several initial proposi-
tions made in response to these invitations are currently
in development. International collaborations with sister
PCD registries in other countries have been fostered
during networking opportunities created by attendance
at key international meetings. Links were initially estab-
lished at the International Myeloma Workshop in Rome
in 2015, and then further consolidated with a proposal
currently under development for a comparative study on
health-care models, first-line therapy and response in
MM in collaborating countries. International data shar-
ing and security issues may prove to be an obstacle to
participation for some countries.
Myeloma 1000
The Myeloma 1000 project, a sub-study of the MRDR,
aims to establish a repository of 1000 fully annotated
peripheral blood specimens from MGUS patients and a
further 1000 from MM patients. Samples are collected
from consenting participants on the registry at the time
of diagnosis, after completing a separate consent with an
‘opt in’ model by qualified staff not directly associated
with the registry. Newly diagnosed patients appropriate
for this sub-study are identified by treating clinicians at
each site prior to initiation of any treatment. After ap-
propriate initial discussion with the treating clinician,
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formal consent for participation is obtained. Peripheral
blood samples are collected on site using pre-prepared
kits and returned to the MRDR using the express post
packs provided for inclusion in the biobank at no cost to
the sites. These samples will be available for future
correlative studies including, the study of circulating
biomarkers and molecular epidemiological questions.
Through linking prospective, long-term clinical data
with biological data provided by these stored samples
it is anticipated that the Myeloma 1000 project will
provide insight into the mechanisms underlying dis-
ease progression so as to inform optimal treatment
strategies for MM and related diseases. Currently the
Myeloma 1000 project has stored samples from 46
MM and 55 MGUS patients accrued over a period of
20 months.
Conclusions
The benefits of clinical registries are well established. By
providing a clinically relevant and credible means of
monitoring patient populations, therapies and outcomes,
they enable high quality studies of real world data in
even rare diseases. Prospectively collected datasets that
are manageable for data collectors without compromis-
ing the complexity and comprehensiveness of data pro-
vide ample opportunities for integration and analysis to
address a multitude of clinical questions currently and
into the future. Establishing a national registry is chal-
lenging, but the MRDR is a valuable ANZ resource with
data on over 1250 patients to date and with potential for
national and international research collaborations.
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